Navigation Links
PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors
Date:2/12/2008

Larry G. Pickering Resigns from the Board of Directors

NEW YORK, Feb. 12 /PRNewswire/ -- PeriCor Therapeutics today announced the appointment of K. Tucker Andersen as a director of the Company's Board of Directors effective February 7, 2008. Mr. Andersen is a retired portfolio manager and security analyst and the sole proprietor of the consulting firm Above All Advisors, LLC. The Company also announced that on February 1, 2008, Larry G. Pickering resigned as a director of the Company.

"We are very pleased that Tucker has agreed to join the PeriCor Board of Directors," stated Richard R. Stover, President and CEO of PeriCor Therapeutics. "Tucker brings a wealth of financial and corporate experience to the company. His extensive background as an investor and director of a variety of businesses will be an asset to the development of PeriCor Therapeutics." Mr. Stover further stated, "We would also like to thank Larry Pickering for his dedication and service to the Company. Mr. Pickering made valuable contributions to the strategic direction of PeriCor during his time as a director and we wish him well in the future."

Before founding Above All Advisors, LLC, Mr. Andersen was co-Managing Partner and Chief Investment Strategist for Cumberland Associates. He currently serves as chairman of Artificial Cell Technologies, a biotechnology-nanotechnology venture stage firm and serves on the boards of the International Foundation for Research in Experimental Economics (headed by Nobel Laureate Vernon Smith), the Cato Institute, GOPAC, the Questech Corporation, the Foundation for the Advancement of Monetary Education, and the Warren, Connecticut Congregational Church. He is also on the advisory board of Brook Venture Partners, and has recently become a Founding Partner of Value Insight Partners, a fund of funds investing in a select group of value oriented hedge funds with diverse investment strategies. While retired from his position as vice-president of the board of the Phillips Exeter Academy, he still serves as a member of Exeter's investment committee which he formerly chaired. Mr. Andersen is a Chartered Financial Analyst and Associate Member of the Society of Actuaries. He received his Bachelor's degree in Quantitative Studies from Wesleyan University and is the recipient of Wesleyan's Distinguished Alumnus Award and of the Founder's Day Award from Exeter.

About PeriCor Therapeutics

PeriCor Therapeutics, Inc. is a privately-held specialty biopharmaceutical company focused on the development and commercialization of a new class of medicines, adenosine regulating agents, to prevent the perioperative complications of surgery and improve the treatment and outcomes of acute cardiovascular care.


'/>"/>
SOURCE PeriCor Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
3. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
4. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
5. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
6. Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine
7. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
8. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
9. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
10. Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
11. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... -- According to the new market ... Instruments, Automated Cell Expansion System), Cells Types (Human, ... Cancer, and Cell-Based Research), End-users (Biopharmaceutical and Biotechnology ... Trends, Growth, Share, Size and Forecast to 2022", ... expansion market is expected to reach USD 18.74 ...
(Date:12/5/2016)... Mich. , Dec. 5, 2016 NxGen MDx announced today ... bringing the test in house, we,ve been able to improve customer service ... for patients," says Alan Mack , CEO of NxGen MDx. ... , , ... test volume has led to more job opportunities at the Grand Rapid ...
(Date:12/5/2016)... -- The U.S. Biotechnology industry is the ... revenue and some $890 billion of total market value. In ... and this figure is expected to exceed $220 billion ... four equities for assessment: Northwest Biotherapeutics Inc. (NASDAQ: ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ACOR ...
(Date:12/4/2016)...  In five studies being presented today during the ... Exposition in San Diego , researchers ... delivery of life-saving treatments to patients with a variety ... carry therapies directly to the sites in the body ... substantial advantage over traditional, systemic methods. The studies highlight ...
Breaking Biology Technology:
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):